TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 2, 2015, Pages 327-339

  Gambara, Guido ^a   Desideri, Marianna ^b   Stoppacciaro, Antonella ^c   Padula, Fabrizio ^a   De Cesaris, Paola ^d   Starace, Donatella ^a   Tubaro, Andrea ^c   del Bufalo, Donatella ^b   Filippini, Antonio ^a   Ziparo, Elio ^a   Riccioli, Anna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Apoptosis; IRF 3; Poly I:C; Prostate cancer; Toll like receptor

Indexed keywords

MUS;

ANDROGEN; INTERFERON REGULATORY FACTOR 3; IRF3 PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; CELL LINE; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; MALE; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; PROSTATE; TUMOR CELL LINE;

ANDROGENS; ANIMALS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTERFERON REGULATORY FACTOR-3; MALE; MICE; MICE, INBRED NOD; PROSTATE;

EID: 84921752366     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12379     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Rock FL, Hardiman G, Timans JC, et al. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA. 1998; 95: 588-93.
3. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003; 21: 335-76.
4. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2: 675-80.
5. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004; 5: 987-95.
6. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol. 2013; 13: 453-60.
7. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004; 4: 499-511.
8. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem. 2007; 76: 447-80.
9. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009; 9: 57-63.
10. Galli R, Paone A, Fabbri M, et al. Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARbeta and tumor regression. Proc Natl Acad Sci USA. 2013; 110: 9812-7.
11. Salaun B, Zitvogel L, Asselin-Paturel C, et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 2011; 71: 1607-14.
12. Gambara G, De Cesaris P, De Nunzio C, et al. Toll-like receptors in prostate infection and cancer between bench and bedside. J Cell Mol Med. 2013; 17: 713-22.
13. Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer. J Immunol. 2012; 188: 5357-64.
14. Khvalevsky E, Rivkin L, Rachmilewitz J, et al. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem. 2007; 100: 1301-12.
15. Paone A, Starace D, Galli R, et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis. 2008; 29: 1334-42.
16. Salaun B, Coste I, Rissoan MC, et al. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006; 176: 4894-901.
17. Salaun B, Lebecque S, Matikainen S, et al. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res. 2007; 13: 4565-74.
18. Galli R, Starace D, Busa R, et al. TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J Immunol. 2010; 184: 6658-69.
19. Paone A, Galli R, Gabellini C, et al. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia. 2010; 12: 539-49.
20. Jiang Z, Mak TW, Sen G, et al. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci U S A. 2004; 101: 3533-8.
21. Fitzgerald KA, McWhirter SM, Faia KL, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003; 4: 491-6.
22. McWhirter SM, Fitzgerald KA, Rosains J, et al. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc Natl Acad Sci USA. 2004; 101: 233-8.
23. Au WC, Moore PA, Lowther W, et al. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci USA. 1995; 92: 11657-61.
24. Vince JE, Tschopp J. IRF-3 partners Bax in a viral-induced dance macabre. EMBO J. 2010; 29: 1627-8.
25. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010; 9: 293-307.
26. Bello D, Webber MM, Kleinman HK, et al. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis. 1997; 18: 1215-23.
27. Chattopadhyay S, Marques JT, Yamashita M, et al. Viral apoptosis is induced by IRF-3-mediated activation of Bax. EMBO J. 2010; 29: 1762-73.
28. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994; 54: 2577-81.
29. Hiscott J. Triggering the innate antiviral response through IRF-3 activation. J Biol Chem. 2007; 282: 15325-9.
30. Harashima N, Inao T, Imamura R, et al. Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother. 2012; 61: 667-76.
31. Peters K, Chattopadhyay S, Sen GC. IRF-3 activation by Sendai virus infection is required for cellular apoptosis and avoidance of persistence. J Virol. 2008; 82: 3500-8.
32. Besch R, Poeck H, Hohenauer T, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest. 2009; 119: 2399-411.
33. Chattopadhyay S, Sen GC. IRF-3 and Bax: a deadly affair. Cell Cycle. 2010; 9: 2479-80.
34. Weber A, Kirejczyk Z, Besch R, et al. Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ. 2010; 17: 942-51.
35. Evan GI. Can't kick that oncogene habit. Cancer Cell. 2006; 10: 345-7.
36. Chin AI, Miyahira AK, Covarrubias A, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res. 2010; 70: 2595-603.
37. Berge M, Bonnin P, Sulpice E, et al. Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol. 2010; 177: 3192-201.
38. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452: 591-7.
39. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother. 2011; 60: 217-26.
40. Schulz WA, Alexa A, Jung V, et al. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer. 2007; 6: 14.